BioPharmSignal logoBioPharmSignal

Biotech News

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Chemomab Therapeutics (CMMB)Chemomab TherapeuticsClinical readout

CMMB (CMMB) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is cmmb.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

CMMBChemomab Therapeutics2026-07-08 11:30 EST

Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis

KYMRKymera2026-03-28 15:00 EST

Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting

KYMRKymera2026-06-25 11:00 EST

Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026

NRIXNurix Therapeutics2026-05-14 20:06 EST

Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting

AVTXAvalo Therapeutics2026-05-05 20:01 EST

Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa

GPCRStructure Therapeutics2026-03-16 11:00 EST

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

REGNRegeneron Pharmaceuticals2026-04-21 14:30 EST

Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial

CMMBChemomab Therapeutics2026-05-14 12:00 EST

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

REGNRegeneron Pharmaceuticals2026-05-16 00:19 EST

Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

SNGXSOLIGENIX2026-04-28 11:30 EST

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

View all latest news

Chemomab Therapeutics

Chemomab Therapeutics is a biotechnology company focused on fibrosis and inflammatory disease biology. Its story is centered on targeting tough chronic conditions where disease-modifying therapies are still needed.

Recent company news

CMMBChemomab Therapeutics2026-07-08 11:30 EST

Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis

CMMBChemomab Therapeutics2026-05-14 12:00 EST

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

CMMBChemomab Therapeutics2026-03-19 12:00 EST

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

CMMBChemomab Therapeutics2026-02-17 13:00 EST

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

CMMBChemomab Therapeutics2025-12-02 13:00 EST

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Stock data

Close
1.42 USD
Market cap
12.53M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States